Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure

P. Pacher, L. Liaudet, P. Bai, L. Virag, J. G. Mabley, G. Haskó, Csaba Szabo

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX. PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p). Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones. Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle. Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.

Original languageEnglish
Pages (from-to)862-867
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume300
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Doxorubicin
Heart Failure
Oxidative Stress
Genetic Suppression
Enzyme Activation
Anthracyclines
Metalloproteases
Creatine Kinase
L-Lactate Dehydrogenase
Oxidants
DNA Damage
Pharmacology
Anti-Bacterial Agents
Injections
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride
Wounds and Injuries
Therapeutics
Serum

ASJC Scopus subject areas

  • Pharmacology

Cite this

Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. / Pacher, P.; Liaudet, L.; Bai, P.; Virag, L.; Mabley, J. G.; Haskó, G.; Szabo, Csaba.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 300, No. 3, 2002, p. 862-867.

Research output: Contribution to journalArticle

Pacher, P. ; Liaudet, L. ; Bai, P. ; Virag, L. ; Mabley, J. G. ; Haskó, G. ; Szabo, Csaba. / Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. In: Journal of Pharmacology and Experimental Therapeutics. 2002 ; Vol. 300, No. 3. pp. 862-867.
@article{c6d9f0cd07d84abb85e1e910e48d2416,
title = "Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure",
abstract = "Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX. PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p). Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones. Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle. Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.",
author = "P. Pacher and L. Liaudet and P. Bai and L. Virag and Mabley, {J. G.} and G. Hask{\'o} and Csaba Szabo",
year = "2002",
doi = "10.1124/jpet.300.3.862",
language = "English",
volume = "300",
pages = "862--867",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure

AU - Pacher, P.

AU - Liaudet, L.

AU - Bai, P.

AU - Virag, L.

AU - Mabley, J. G.

AU - Haskó, G.

AU - Szabo, Csaba

PY - 2002

Y1 - 2002

N2 - Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX. PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p). Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones. Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle. Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.

AB - Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX. PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p). Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones. Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle. Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036175161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036175161&partnerID=8YFLogxK

U2 - 10.1124/jpet.300.3.862

DO - 10.1124/jpet.300.3.862

M3 - Article

C2 - 11861791

AN - SCOPUS:0036175161

VL - 300

SP - 862

EP - 867

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -